Biotech Assistant
Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

ANGPTL3 base-editing study reports sustained protein lowering in nonhuman primates

Academic source · Nature

Source published:

Site published: 2026-11-08 · Updated: 2026-11-08

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What the paper reports

A Nature study delivered guide RNA and base-editor mRNA in GalNAc lipid nanoparticles to inactivate liver ANGPTL3. Nonhuman primates showed mean ANGPTL3 protein reductions exceeding 90%, with durability assessed through three years after one dose. Lipid reductions were observed in animal models. Human liver-cell testing assessed selected off-target sites; the paper does not report human clinical efficacy.

Why this paper is included

Potential business implication: durable liver editing may support further delivery and analytical development, while broader off-target assessment and clinical safety remain essential.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP In Vivo Cell Engineering & Gene Editing

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

WuXi AppTec / WuXi TIDESCrystal NAXModernaBioNTech SEArcturus Therapeutics
Explore field companies →Explore literature →

Related updates

Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTACAsk AI ↗
Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

Companies mentionedModerna ↗
mRNA / LNPAsk AI ↗
Moderna (ACCESS Newswire via Newscom)

Moderna reports Canadian authorization of flu and combined flu–COVID mRNA vaccines

Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.

Companies mentionedModerna ↗
mRNA / LNPAsk AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗